• 1
    Schulman LL, Weinberg AD, McGregor CC. Influence of donor and recipient HLA locus mismatching on development of obliterative bronchiolitis after lung transplantation. Am J Respir Crit Care Med 2001; 163: 437442.
  • 2
    Heng D, Sharples LD, McNeil K, Stewart S, Wreghitt T, Wallwork J. Bronchiolitis obliterans syndrome: Incidence, natural history, prognosis and risk factors. J Heart Lung Transplant 1998; 17: 12551263.
  • 3
    Sharples LD, McNeil K, Stewart S, Wallwork J. Risk factors for bronchiolitis obliterans: A systematic review of recent publications. J Heart Lung Transplant 2002; 21: 271281.
  • 4
    Zamora MR. Use of cytomegalovirus immune globulin and ganciclovir for the prevention of cytomegalovirus disease in lung transplantation. Transpl Infect Dis 2001; 3(Suppl 2): 4956.
  • 5
    Ettinger NA, Bailey TC, Trulock EP et al. Cytomegalovirus infection and pneumonitis. Impact after isolated lung transplantation. Am Rev Respir Dis 1993; 147: 10171023.
  • 6
    Couchoud C. Cytomegalovirus prophylaxis with antiviral agents for solid organ transplantation. Cochrane Database Syst Rev 2000; 2: CD001320.
  • 7
    Weill D, Lock BJ, Wewers DL et al. Combination prophylaxis with ganciclovir and cytomegalovirus (CMV) immune globulin after lung transplantation: Effective CMV prevention following daclizumab induction. Am J Transplant 2003; 3: 492496.
  • 8
    Brumble LM, Milstone AP, Loyd JE et al. Prevention of cytomegalovirus infection and disease after lung transplantation. Results using a unique regimen employing delayed ganciclovir. Chest 2002; 121: 407414.
  • 9
    Speich R, Thurnheer R, Gaspert A, Weder W, Boehler A. Efficacy and cost effectiveness of oral ganciclovir in the prevention of cytomegalovirus disease after lung transplantation. Transplantation 1999; 67: 315320.
  • 10
    Wreghitt TG, Abel SJ, McNeil K et al. Intravenous ganciclovir prophylaxis for cytomegalovirus in heart, heart-lung, and lung transplant recipients. Transpl Int 1999; 12: 254260.
  • 11
    Gutierrez CA, Chaparro C, Krajden M, Winton T, Kesten S. Cytomegalovirus viremia in lung transplant recipients receiving ganciclovir and immune globulin. Chest 1998; 113: 924932.
  • 12
    Duncan SR, Grgurich WF, Iacono AT et al. A comparison of ganciclovir and acyclovir to prevent cytomegalovirus after lung transplantation. Am J Respir Crit Care Med 1994; 150: 146152.
  • 13
    Pescovitz MD, Pruett TL, Gonwa T et al. Oral ganciclovir dosing in transplant recipients and dialysis patients based on renal function. Transplantation 1998; 66: 11041107.
  • 14
    Pescovitz MD, Rabkin J, Merion RM et al. Valganciclovir results in improved oral absorption of ganciclovir in liver transplant recipients. Antimicrob Agents Chemother 2000; 44: 28112815.
  • 15
    Hertz MI, Jordan C, Savik SK et al. Randomized trial of daily versus three-times-weekly prophylactic ganciclovir after lung and heart-lung transplantation. J Heart Lung Transplant 1998; 17: 913920.
  • 16
    Martin DF, Sierra-Madero J, Walmsley S et al. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med 2002; 346: 11191126.
  • 17
    Paya C, Humar A, Dominguez E et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of CMV disease in solid organ transplant recipients. Am J Transplant 2004; 4: 611620.
  • 18
    Bhorade SM, Sandesara C, Gerrity ER et al. Quantification of cytomegalovirus (CMV) viral load by the hybrid capture assay allows for early detection of CMV disease in lung transplant recipients. J Heart Lung Transplant 2001; 20: 928934.
  • 19
    Weinberg A, Schissel D, Giller R. Molecular methods for cytomegalovirus surveillance in bone marrow transplant recipients. J Clin Microbiol 2002; 40: 42034206.
  • 20
    Weinberg A, Hodges TN, Li S, Cai G, Zamora MR. Comparison of PCR, antigenemia assay, and rapid blood culture for detection and prevention of cytomegalovirus disease after lung transplantation. J Clin Microbiol 2000; 38: 768772.
  • 21
    Weinberg A, Jabs DA, Chou S et al. Mutations conferring foscarnet resistance in a cohort of patients with acquired immunodeficiency syndrome and cytomegalovirus retinitis. J Infect Dis 2003; 187: 777784.
  • 22
    Soghikian MV, Valentine VG, Berry GJ, Patel HR, Robbins RC, Theodore J. Impact of ganciclovir prophylaxis on heart-lung and lung transplant recipients. J Heart Lung Transplant 1996; 15: 881887.
  • 23
    Bailey TC, Trulock EP, Ettinger NA, Storch GA, Cooper JD, Powderly WG. Failure of prophylactic ganciclovir to prevent cytomegalovirus disease in recipients of lung transplants. J Infect Dis 1992; 165: 548552.
  • 24
    Boivin G, Goyette N, Gilbert C et al. Absence of CMV resistance mutations following valganciclovir prophylaxis in a prospective multicentric study in solid organ transplant recipients. J Infect Dis 2004; 189: 16151618.
  • 25
    Caliendo AM, Yen-Lieberman B, Baptista J et al. Comparison of molecular tests for detection and quantification of cell-associated cytomegalovirus DNA. J Clin Microbiol 2003; 41: 35093513.